Similar Search Results

Non-Tariff Barriers and Bargaining in Generic and Off-Patent Pharmaceuticals

Ganapati, Sharat; McKibbin, Rebecca - 2019

Pharmaceutical prices are widely dispersed across countries with comparable quality standards. We study two elements of this dispersion; non-tariff barriers and buyer bargaining power. Under monopoly, generic drug prices are 3-4 times higher in the United States. With 6 or more competitors,...

Persistent link: https://www.econbiz.de/10014108967

Switching Costs, Brand Premia and Behavioral Pricing in the Pharmaceutical Market

Janssen, Aljoscha - 2020

This article examines the market power of branded prescription drugs faced with generic competition. Using prescription-level and matched socioeconomic panel data of the entire Swedish population between 2010 and 2016, I provide evidence for the key role of switching costs. A discontinuity...

Persistent link: https://www.econbiz.de/10014095430

Price Dynamics of Swedish Pharmaceuticals

Janssen, Aljoscha - 2020

This paper investigates price patterns of off-patent pharmaceuticals in Sweden. I show that price dynamics are … competition in which the demand for pharmaceuticals incorporates the known biases of consumers: habit persistence and brand … preferences. Using the regulated market of Swedish pharmaceuticals, I show that price dynamics may help in identifying possible …

Persistent link: https://www.econbiz.de/10014095437

International Price Regulations in the Pharmaceutical Sector : A Common Model to Sharing the Benefits

Levaggi, Rosella; Capri, Stefano - 2005

In this article we analyse the market for drugs in health care markets where third payers (an insurance company or a government agency) bear the cost and we suggest a common and transparent methodology to set the price for new drugs as well as active principles for which an alternative already...

Persistent link: https://www.econbiz.de/10014028693

The Competitive Efficacy of Divestitures : An Empirical Analysis of Generic Drug Markets

Chen, Viola; Garmon, Christopher; Rios, Kenneth; … - 2022

One approach that antitrust enforcement authorities use to address potentially anticompetitive mergers is to seek divestitures in specific, competitively problematic overlap markets while allowing the rest of the merger to consummate. We evaluate the efficacy of this approach by studying...

Persistent link: https://www.econbiz.de/10013295031

Pricing for Medicine Innovation : A Regulatory Approach to Support Drug Development and Patient Access

Collington, Rosie; Lazonick, William - 2022

The United States represents the world’s largest market for pharmaceutical drugs. It is also the only advanced economy in the world that does not regulate drug prices. There is no upper threshold for the prices of medicines in the United States. List prices are instead set by manufacturers in...

Persistent link: https://www.econbiz.de/10013295329

Excessive Pricing of Pharmaceuticals in EU Law : Balancing Competition, Innovation and Regulation

Akker, Ilan; Sauter, Wolf - 2022

Abstract: This article discusses the prosecution of excessive pricing cases regarding pharmaceutical products under EU law in its regulatory context. In recent years the legal framework for the pursuit of such cases, based on the United Brands precedent, has been established more firmly. The...

Persistent link: https://www.econbiz.de/10013299479

Should product-specific advertisement be regulated in pharmaceutical markets?

Ishida, Junichiro; Takahara, Tsuyoshi - 2022

This paper examines the optimal content regulation of DTCA by comparing two forms of DTCA-product-specific and category-specific-and identifies a key tradeoff which underlies this policy debate. Our analysis suggests that the optimal form of DTCA depends crucially on the cost effectiveness of...

Persistent link: https://www.econbiz.de/10013329470

The Value of Pharmacy Benefit Management

Mulligan, Casey B. - National Bureau of Economic Research - 2022

In theory, equilibrium profits for drug patent holders would not involve significant restraints on production and patient utilization if the market had a mechanism for two-part pricing (Oi 1971) or quantity commitments (Murphy, Snyder, and Topel 2014). In fact, patent expiration has little...

Persistent link: https://www.econbiz.de/10013334448

The Impact of Pharmaceutical Policy Measures : A Structural-Break Approach

Barros, Pedro P.; Nunes, Luis C. - 2009

Pharmaceutical spending in many other countries has had a steep increase in the last decade. The Portuguese Government has adopted several measures to reduce pharmaceutical expenditure growth, ranging from increased co-payments to price decreases determined administratively. Promotion of generic...

Persistent link: https://www.econbiz.de/10014209702